Marco Franzosi

From patient-level data, to patient-level impact

Basel, Basel, Switzerland

About

📈 Strategy + execution in Evidence Generation 📋 Experience: Big pharma + consulting + start-ups + audit Skills: simplify complexity ¦ analyze and resolve ¦ engage with leaders ¦ communicate strategically Impact: operational effectiveness ¦ transformation ¦ growth Therapeutic area experience: Women's health, nephrology, benign hematology, oncology (both solid and heme). Specialties: - Real-World data and Real-World Evidence - Digital Health (implementation, policy, co-author) - Project Management of large cross-functional projects - Process and organization re-engineering I thrive in teams where sharp minds work together to solve problems that matter. Education (M. Eng + M.Sc.) in Technology and Sciences.

Experience

  • Growth and Partnerships at Health and digital ventures
    May 2026 - Present · 3 mos

    Working with founders, to explore, expand and solidify their B2B revenues.

  • RWE Director at Ipsos in Switzerland
    Aug 2025 - May 2026 · 10 mos

    Design and conduct Non Interventional Studies for pharma, biotech and medtech companies.

  • Life Science Advisor at DataArt
    Jan 2025 - Aug 2025 · 8 mos

    Addressing complex LifeScience use cases through bespoke data and analytics solutions

  • Principal, Real World Solutions at IQVIA
    Oct 2022 - Jan 2025 · 2 yrs 4 mos

  • Private Investor at Swiss Health Angels - Business Angel Association
    Jan 2020 - Dec 2024 · 5 yrs

    - Drug Development venture (currently in Phase II). Stage: IPO in June 2022 - Diagnostics venture (nanotechnology for tissue analysis). Stage: early commercial revenue - Lab technology venture (chip-based protein detection). Stage: early commercial revenue - Diagnostics venture (novel platform for detection of food contaminants). Stage: full PoC, pre-commercial - CleanTech venture (vertical farming and democratised food production). Stage: full commercial revenues, scale-up - BioTech venture (compounds to target previously-undruggable factors). Stage: Phase II, raising a Series C funding round.